Fox Run Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$102K Buy
+20,875
New +$112K 0.01% 910
2025
Q1
– Sell
-19,247
Closed -$92.2K – 1261
2024
Q4
$92.2K Sell
19,247
-14,199
-42% -$68.2K 0.02% 812
2024
Q3
$157K Buy
+33,446
New +$179K 0.03% 698
2023
Q3
– Sell
-21,890
Closed -$144K – 1015
2023
Q2
$144K Buy
+21,890
New +$140K 0.04% 617
2018
Q3
– Sell
-28,611
Closed -$545K – 837
2018
Q2
$545K Buy
28,611
+5,516
+24% +$92.2K 0.17% 205
2018
Q1
$389K Buy
+23,095
New +$387K 0.09% 401
2017
Q4
– Sell
-38,900
Closed -$696K – 905
2017
Q3
$696K Buy
+38,900
New +$651K 0.2% 167
2017
Q2
– Sell
-19,000
Closed -$266K – 856
2017
Q1
$266K Buy
+19,000
New +$271K 0.11% 406

Other funds holding VNDA

Fox Run Management's VNDA Position: Q3 2026 in Review

Fox Run Management opened a new position in Vanda Pharmaceuticals (VNDA) in Q3 2026: 20,875 shares worth $102K. The stake represents 0.01% of the portfolio and ranks #910 among its holdings. This is a return to the name: Fox Run Management previously reported a position in VNDA as recently as Q4 2024.

Fox Run Management first reported a position in VNDA in Q1 2017 and has held it in 8 quarters since. The position peaked at $696K in Q3 2017. 151 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

  • Fox Run Management held 20,875 shares of Vanda Pharmaceuticals worth $102K as of Q3 2026.
  • Vanda Pharmaceuticals was a new Fox Run Management position in Q3 2026.
  • Vanda Pharmaceuticals made up 0.01% of Fox Run Management's portfolio in Q3 2026, its #910 holding.
  • Fox Run Management first reported a position in Vanda Pharmaceuticals in Q1 2017 and has held it in 8 quarters since.
  • Fox Run Management's Vanda Pharmaceuticals position peaked at $696K in Q3 2017.
  • 151 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.